ArticleUrolithiasis2026
Urinary volatilomics for biomarker discovery in kidney stone patients and healthy controls.
Article in Urolithiasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrolithiasis is a prevalent and recurrent condition with a rising incidence worldwide, largely attributed to modifiable lifestyle factors, including diet. Novel, non-invasive biomarkers are needed to improve early diagnosis, recurrence monitoring, and personalized prevention. This study aimed to identify urinary volatile organic compounds (VOCs) that differentiate healthy individuals from kidney stone formers and to explore their associations with fermented food intake. Using dynamic headspace Vacuum in-tube extraction gas chromatography-mass spectrometry (DHS-V-ITEX-GC-MS), 24-h urine samples were analyzed to identify potential volatile biomarkers related to kidney stone risk. This case-control study included 232 patients with recurrent kidney stone disease and 168 healthy controls enrolled in the Swiss Kidney Stone Cohort. Urine samples were analyzed using untargeted volatilomic profiling. Data were normalized, quality-filtered, and adjusted for relevant confounders, including study center, sex, age, body mass index, smoking status, and diabetes status. Uni- and multivariate statistical analyses were applied to identify discriminative features, followed by metabolite identification. Seventy-seven metabolites differed significantly between kidney stone formers and controls. Octane, 1,1'-oxybis- and 6-methyl-5-hepten-2-one were present at higher levels in controls, whereas acetic acid and propanoic acid were detected at higher levels in participants with kidney stones. Among these metabolites, three were associated with fermented food consumption, with 3-nonen-2-one emerging as a potential mediator of the association between coffee consumption and reduced kidney stone risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.